Community/Retail

Tyler Redelico, pharmacy student at Rutgers University's Ernest Mario School of Pharmacy, gives advice to students heading to pharmacy school.

Simon Lu, pharmacy student at Rutgers University's Ernest Mario School of Pharmacy, shares a fun fact he learned in pharmacy school.

Repeated requests for early refills may be a sign that a medication is being misused or diverted.

The better educated the patient, the better medicated the patient will be.

Do you carefully examine the explanation of benefits forms that you receive from your health insurer?

Novartis today announced that it has completed effective July 31, 2015 the divestiture of its influenza vaccine unit to CSL Limited.

Current medication regimens used in bipolar I disorder produce suboptimal patient outcomes more often than not.

The American Pharmacists Association Foundation today announced Elizabeth K. Keyes, BSPharm, will serve as Interim Executive Director for APhA Foundation.

Discount Drug Mart has opened its first MetroHealth walk-in clinic at the pharmacy chain's Parma Heights store, located at 6476 York Road.

Pharmacists should be aware that a clopidogrel tablet found in a bottle of hydrochlorothiazide tablets has prompted a product recall.

The term innovation is frequently used in today's lexicon. Whether it is used as a verb (to innovate) or an adjective to describe an activity (innovative), the term appears in all sectors of society.

Jamie Mitchell Mask, PharmD, a clinical community pharmacist consultant with Creative Pharmacist who still practices part time in Mendenhall, Missippi, joins the Show.

A man wearing a ninja mask and carrying a martial-arts sword recently robbed a Walgreens pharmacy in California.

RediClinic has announced that it will donate a total of $40,000 to 8 YMCAs serving the greater Baltimore/Washington DC, Philadelphia, and Seattle areas.

Will the new partnership between CVS Health and IBM bring about real disruption in community pharmacy?

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

Teva Pharmaceutical Industries Ltd. and Immuneering Corporation announced that the companies have entered into an agreement in which Teva will purchase a 51% equity share of the company.

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.

Making birth control available OTC would improve women's access to oral contraceptives while producing dramatic cost savings, a new National Center for Policy Analysis (NCPA) brief argues.

Laughter is the best medicine that never requires a co-pay.

Patients with uncontrolled hypertension have better blood pressure control when pharmacists are included in their care teams.

Up to 13% of patients considered to have chronic obstructive pulmonary disease (COPD) under current criteria were recently found to be misdiagnosed.

A woman is suing an Oregon pharmacist and technician for $680,000 for allegedly giving her the wrong medication, which has impacted her ability to conceive.

The FDA has granted priority review to Merck's chronic hepatitis C virus (HCV) treatment candidate grazoprevir/elbasvir.

This weekly video program highlights the latest in pharmacy news, product news, and more.

Many new mothers do not receive advice from physicians on how to care for their infants, which opens opportunities for pharmacists to provide patient education.

A new report from the Centers for Medicare and Medicaid Services finds that prescription drug spending increased 12.6 percent in 2014, the highest growth rate since 2002.

Two New Yorkers have died in a Legionnaires' disease outbreak, and now a college in Pennsylvania is treating its cooling towers after an employee tested positive for the flu-like disease.

The FDA today approved azelaic acid foam 15% (Finacea) to treat inflammatory papules and pustules of mild to moderate rosacea.

Eisai Co., Ltd. and Halozyme Therapeutics, Inc. announced that they have signed a clinical collaboration agreement to evaluate Eisai's anticancer agent eribulin mesylate.